Business
Medicenna shares resume trading under the symbol "MDNA"
Medicenna shares resume trading under the symbol "MDNA" Canada NewsWire TORONTO ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna shares resume trading under the symbol \"MDNA\"\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, March 8, 2017\n\n\n\nTORONTO and HOUSTON, March 8, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSXV: MDNA) today announced that the Company's shares have resumed trading on the TSX Venture Exchange (\"TSXV\") under the symbol \"MDNA\".\n\nMedicenna is a clinical stage immunotherapy company developing novel, first-in-class Interleukin-4 Empowered Cytokines™ (IL4-ECs) designed to target tumors that over-express the IL-4 receptor (IL4R). These proprietary Molecular Trojan Horses consist of IL-4 Superkines™ fused to cell-killing payloads. The lead IL4-EC, MDNA55, has completed three clinical trials with promising results in 72 patients including 66 adults with recurrent glioblastoma (rGB), the most common and uniformly fatal form of brain cancer. Medicenna BioPharma, the Company's Houston, Texas based wholly owned subsidiary, is currently enrolling rGB patients in a Phase 2b clinical trial at leading brain cancer centres in the US.\n\n\"We are pleased with the market's interest in our immuno-oncology platform, as evidenced by demand increasing the size of our recently completed private placement to $4 million,\" said Dr. Fahar Merchant, President and CEO of Medicenna. \"The successful completion of this financing and go-public transaction is an important milestone in the Company's history, and we look forward to additional institutional investor interest following our listing on the TSXV.\"\n\nMedicenna has raised approximately $10 million by way of private placements over the past twelve months and the recently competed private placement of $4 million brings the total funds raised to approximately $14 million.  In addition to these proceeds, the Company has access to up to US$14.1 million by way of a product development grant from the Cancer Prevention Research Institute of Texas (CPRIT).\n\nMDNA55 has secured Orphan Drug Status from the United States Food and Drug ...